Prevail Partners, an affiliate of Prevail CInfoWorks, has led a USD10 million Series A funding round in PolyPhotonix Limited, a developer of a noninvasive treatment for diabetic retinopathy.
Prevail Partners, an affiliate of Prevail CInfoWorks, has led a USD10 million Series A funding round in PolyPhotonix Limited, a developer of a noninvasive treatment for diabetic retinopathy.
The investment will be made on the commencement of an FDA regulated human clinical trial of PolyPhotonix’s Noctura 400 Sleep Mask.
Prevail InfoWorks Inc, is a global company based in Philadelphia in the United States, providing biotech, pharmaceutical, medical device and diagnostics companies with the most innovative and complete technology and service solutions for their clinical development. The deal will leverage Prevail InfoWorks’ capabilities and technological expertise for achieving the highest quality data in the shortest possible time to expedite the clinical trial process.
